scispace - formally typeset
Open AccessJournal ArticleDOI

Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots.

Jacqui Wise
- 11 Mar 2021 - 
- Vol. 372
Reads0
Chats0
TLDR
Denmark has temporarily suspended use of the Oxford-AstraZeneca covid-19 vaccine as a precautionary move after reports of blood clots and one death.
Abstract
Denmark has temporarily suspended use of the Oxford-AstraZeneca covid-19 vaccine as a precautionary move after reports of blood clots and one death. However, the European Medicines Agency (EMA) and the UK’s regulatory body have said that there is no indication that vaccination is linked to thromboembolic events. Eight other countries—Norway, Iceland, Austria, Estonia, Lithuania, Luxembourg, Italy, and Latvia—have also suspended use of AstraZeneca’s vaccine. The decisions are a further setback for Europe’s vaccination campaign, which has struggled to pick up speed, partly because of delays in delivering the AstraZeneca vaccine. The Danish Health Authority said that one person in Denmark had died after receiving the AstraZeneca vaccine and that it would suspend the drug’s use for two weeks while the case was investigated. “It is important to point out that we have not terminated the use of the AstraZeneca vaccine—we are just pausing its use,” said the Danish Health Authority’s director, Soren Brostrom. On 10 …

read more

Citations
More filters
Journal ArticleDOI

Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

TL;DR: The current study systematically reviewed, summarized and meta-analyzed the clinical features of the vaccines in clinical trials to provide a better estimate of their efficacy, side effects and immunogenicity and found the adenovirus-vectored and mRNA-based vaccines showed the highest efficacy after first and second doses, respectively.
Journal ArticleDOI

Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines

TL;DR: An updated perspective is provided on the current challenges posed by the emergence of novel SARS-CoV-2 mutants/variants and the evolution of diagnostic techniques to enable their detection and the development, formulation, working mechanisms, advantages, and drawbacks of some of the most used vaccines/therapeutic drugs.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -